CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Escudier, B; Sharma, P; McDermott, DF; George, S; Hammers, HJ; Srinivas, S; Tykodi, SS; Sosman, JA; Procopio, G; Plimack, ER; Castellano, D; Gurney, H; Donskov, F; Peltola, K; Wagstaff, J; Gauler, TC; Ueda, T; Zhao, HY; Waxman, IM; Motzer, RJ

Escudier, B (reprint author), Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif, France.

EUROPEAN UROLOGY, 2017; 72 (6): 962

Abstract

Background: The randomized, phase 3 CheckMate 025 study of nivolumab (n = 410) versus everolimus (n = 411) in previously treated adults (75% male; 88%......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索